Table of Contents
CURRENT MARKET SIZE
- Antibiotic Sales
- Antiviral Sales
- Antifungal Sales
ADDRESSABLE PATIENT POPULATION
- Bacterial Infections
- Viral infections
- Human Immunodeficiency Virus (HIV)
- Hepatitis B (HBV)
- Hepatitis C (HCV)
CURRENT TREATMENTS
- Antibacterial Agents
- Antiviral Agents- HIV
- Antiviral Agents- HCV/HBV
ANTI-INFECTIVES SALES DRIVERS
ANTI-INFECTIVE SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY DRUGS LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY ANTI-INFECTIVES DRUG LAUNCHES BY 2010
- Anidulafungin (Pfizer)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Aptivus (Boehringer Ingelheim)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Aplaviroc (GlaxoSmithKline)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Ceftobiprole (Johnson & Johnson)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Garenoxicin (Schering-Plough)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- GW695634 (GlaxoSmithKline)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Maraviroc (Pfizer)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- MK-0518 (Merck & Co)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Retapamulin (GlaxoSmithKline)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Telbivudine (Novartis)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management and clinical expertise
- Competition within the marketplace/ gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- TMC-114 (Johnson & Johnson/Tibotec Pharma)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Tygacil (Wyeth)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Vicriviroc (Schering-Plough)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- VX-950 (Vertex Pharmaceuticals)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumption
- Competitor Ratio Analysis
- Zeven (Pfizer)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - COMPANIES
| 
View Cart
